Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah, but what good is your incessant complaining do to your investment. Is this your first biotech investment? If you’re not accustomed to it, you’ll be better off with CDs. It’s your right to complain but once in a while give it a rest.
Tired of watching my stupid investment get destroyed, and all the “lists of products” coming soon....we believe...we hope, we feel, we think....
How’s that court case going? I am sure the great CEO we have has already spent the money he thinks he is going to win..
I just happened to see the year you posted. What needs to happen is a change of administration, a change of leadership in DC., IMO.
Well Jess, I actually just picked a random date. I wasn't aware of this MIT study - but the rate our crime is spreading, decline in society and those clawing against capitalism, I am not sure how much time we have. **sigh**
So are you saying sell my shares, take my 55% loss, be happy it wasn't a 65% loss and spend while we still can?
Will be back below $2 by end of next week.
By the way Andecker, 2040 is the year that our society would collapse according to a study conducted by MIT scientists in the 1970s. When asked today if their prediction is on track, their answer was ominous.
I wonder if the good Dr. "don't ruin your families" Ji is buying up shares now to assure the tutes don't align with more shares than SRNE personnel which could single end of milking the cow for those on the SRNE dole?
Interesting, the company I was working for a few years back had a bad year. As a result, the owner had to make some drastic changes. he asked all employees to take a 20% pay cut. Believe it or not, the owner ALSO took the 20% haircut AND got rid of his Volvo and got a Chevy Malibu.
Which is the better leader? "Take as much as you can get away with" Ji or the guy I worked for? Both built their own companies so I know, they can do what they want how they want. Ji should be doing what he can to lower costs to STOP diluting our share worth!! The $7 offer 3 years ago is now worth a lot less due to all the shares flooded on market.
Sorry - I am negative and the bad news for all of you, I am here to stay as I am way down. We are cheering to clear $2.30/share?!?! It will be 2040 by time we get to $8 again if it ever happens.
My plan going forward: Hope for a buyout!! please Please PLEASE!
I for one would honestly love to go after Ji in court to get all of my money back based on all of the lies he's fed to us as investors...i.e. "we have 100% the cure" blah blah blah. He fed us a lot of forward thinking statements that proved to be just a pump in the long run. This guy is a real class act. A lot of my retirement went down the tubes because I believed in what he said and we had genuine opportunity.
It is great to see Ji's significant insider share purchases and the tutes very large accumulations. The Sept. 14 presentation is long overdue! But better late than never!
Sorrento Therapeutics to Participate in Morgan Stanley 20th Annual Global Healthcare Conference September 12-14
September 8, 2022
SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that Henry Ji, Ph.D.,
Chairman, President and Chief Executive Officer, and members of Sorrento’s executive team will participate the 20 th Annual Morgan Stanley Global
Healthcare Conference:
Morgan Stanley 20th Annual Global Healthcare Conference
Location: New York City
Dates: September 12 - 14, 2022
Company Presentation: September 14, 2022, at 8:00 am Eastern time
CEO Fireside Chat Format and Available for 1x1 Investor Meetings
About Sorrento Therapeutics, Inc.
Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments),
autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immunooncology platforms, including key assets such as next-generation tyrosine kinase inhibitors (TKIs), fully human antibodies (“G-MAB™ library”),
immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates (“ADCs”), and oncolytic virus (“Seprehvec™”). Sorrento is also developing potential
antiviral therapies and vaccines against coronaviruses, including STI-1558, COVISHIELD™ and COVIDROPS™; and diagnostic test solutions,
including COVIMARK™.
Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist)
non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel)
(SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica,
and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of postherpetic neuralgia (PHN). RTX has been cleared for a Phase II
trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients. Positive final results from the Phase III Pivotal Trial
C.L.E.A.R. Program for SEMDEXA™, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in
March 2022. ZTlido® was approved by the FDA on February 28, 2018.
For more information visit www.sorrentotherapeutics.com
Our doctor bought 88,888 shares. A strong buy signal
I can see he progress that's being made now has been ignored.
Srne isn't the only pharmaceutical stock down.
Several are down.
Mrna and Pfizer or tho for example.
Great progress has been made.
She follow the naysayer you loose.
Stay the course you stand to benefit
your choice.
Go SRNE
We are down not only because Dr. Ji and our leadership have failed to produce a single product that has produced a solid revenue stream for us.
In addition, Dr. Ji has diluted the # of shares out standing to keep the (very expensive) light on at the old place!
Basic law of economics - increase supply and price comes down.
I've been patient for 6 years and I'll admit it - I feel like a chump.
So much potential squandered. COVID products were a huge opportunity cost to us.
Its not a scan by any merit.
Keep posting what you posts
And see how wrong you be proven
IMO
Go SRNE
Funny how nobody wants to respond to the Covid portfolio, testing in Brazil, Stix in Mexico, Giving himself more stock, but we are desperate.
Someday people will see this scam. Down 80%, wait the whole market is down. I know the big boys and crooked Dr. are loading up...
Lol,desperation setting in.
You can tell when logic is thrown out the window .
Srne either you in to win or you out and disgusted because you didn't buy in time .
Your choice of course.
Srne for the Win
How’s that additional 40 million shares doing for the Great Dr, and the execs doing? 2.5 million for this useless CEO? Let’s go give me the list of earth shattering drugs coming. Time to halt the stock?
Is Abivertinib anti-ARDS still alive?
Myra's boy sums it up...
" Veru down 20% after scheduled Oct 6 advisory committee meeting with FDA on their late stage covid drug EUA . To discuss the high placebo mortality rate and limited participation in trials among other things. Abivertinib and MSC are competing treatments. "
Go Srne
Yes,it's a 2 dollar stock but it's not the only
pharmaceutical stock down
Pfe is down Mrna is down from it's high of
over 300 down to $130's
Rise in price don't give you credibility.
A nice portfolio of drugs do.
Which Srne has.
No one should be criticized for buying or selling with their own money .
Just wait
Topcoat,
It’s unfortunate that most on this board don’t see how this incompetent CEO has no credibility, and until that changes this is a $ 2 stock.
Yea, maybe that monkey pox cure.....
I feel the same Brandywhitneylady... should be much higher according to all their claims.
Buy now or you chance of getting in lower my pass you by .
One piece of good news???????
And the stock struggles to stay over $2. Wait it’s manipulated...I see $ 1.50 soon..
None of us little retail guys know what the big tutes know! Here are 6 reasons they are loading up...over 40% ownership now!
1. SEMDEXA completed PHASE 3 with excellent results.
2. ABIVERTINIB completed PHASE 3 with excellent results.
3. Anti-PD-L1 enrollment for a multi-regional PHASE 3 has completed after outstanding phase 2 results.
4. Mpro broad spectrum oral anti-viral to initiate PHASE 2/ 3 this year. Could include Australia, China, Mexico and US. Scientists expect Covid variants to persist.
5. VIREX prototype field testing for regulatory approval Q3/Q4 2022.
6. RTX two PHASE 2 studies are currently enrolling.
All 6 of these programs are potential blockbusters.
Dia76, you’re one poster we shouldn’t lose in this board. Keep up the good work. Your posts are so invaluable to us. We couldn’t care less if the other posters abstain from posting.
The “big dogs” just want the scraps. Remember when the “big dogs” were “loading up” to get the millions and millions the great Dr.’s Covid products were going to generate. Hey what happened to all of that? The shorts “families” were going to get destroyed....seems like they have been doing very well...wake up here.
Jesspro...Yeah the big tutes have to own over 40% by now...they know what they are doing.
Manipulation, Manipulation, Manipulation, Manipulation, Manipulation.
Can cause a stock PPS to go down.
It's already been documented this stock being manipulated
along with other stocks .
Dr.J has hired some impre
ssive employees .
Mpro is moving .
Now we a drug on FDA FastTrack.
A sign of improvement.
We can wander in the past and future pass us up
It’s because of a incompetent CEO, stop blaming manipulation.
The reasons this stock pps not moving up ?
Is because of day trading and shorts.
Hopefully if the whales are biting it well scare them off.
LOL I'll take whatever you can give!
Look at it this way you won't have to pay any capital gains this year.
You know you're not going to be happy in a higher tax bracket either!
The real question is…..
Should I average down ?
Can’t even give it away.....
Yes, unfortunately like many others on this board that believed the great Dr.’s lies.
Holes in the bottom of the boat make it easier for rats to leave a sinking ship.
Oh wait we're in dry dock.
Hope you can sell your stock soon looks like you've been hopeless with SRNE for years!
Scilex Holding Company (“Scilex”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, today announced that FDA has granted fast track designation for its investigational drug and device product candidate, SP-103. Scilex is a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”).
Scilex is developing SP-103 to be a non-opioid triple-strength, non-aqueous lidocaine topical system for the treatment of acute LBP. If approved, SP-103 could become the first FDA-approved lidocaine topical product for the treatment of acute LBP. Acute LBP can range in intensity from a dull, constant ache to a sudden, sharp sensation that leaves the person incapacitated. According to the CDC in 2020, LBP was the most common type of pain reported by patients, with 25% of U.S. adults reporting LBP in the prior 3 months1. LBP is estimated to have a total potential global market opportunity of approximately $10.0 billion by 2026.2
“We are pleased that the FDA has granted Fast Track Designation for SP-103,” said Dr. Dmitri Lissin, Chief Medical Officer of Scilex. “The FDA's decision to place SP-103 in a category that may enable expedited development and review is an important milestone for Scilex.”
There are currently no approved pharmaceutical treatments specifically indicated for the treatment of acute LBP. The market Scilex intends to address with SP-103, if approved, includes etiologies that are currently treated with non-procedural or non-surgical interventions, and where available treatments provide inadequate pain relief or result in unacceptable adverse effects. These treatments may include NSAIDs, antidepressants and opioids, as well as off-label use of lidocaine patches.
“We are very pleased that the FDA has granted Fast Track designation for the non-opioid SP-103 program, the next generation triple strength formulation of ZTlido®,” said Jaisim Shah, President and Chief Executive Officer of Scilex. There are currently very limited approved treatment options for acute low back pain, a serious condition the prevalence of which continues to rise, leaving this affected group with very limited safe and effective treatment options to date. Receiving this designation underscores the potential of the ZTlido® platform and the need for a new therapy like SP-103 that may improve outcomes for those with this serious debilitating condition.”
The safe and effective treatment of acute LBP represents high unmet needs and creates a large market opportunity. LBP is one of the costliest musculoskeletal conditions in industrialized countries. Experts have estimated that approximately 80% of Americans will experience LBP during their lifetime. The annual prevalence of LBP is 15% to 45% with a point prevalence of approximately 30% in the United States. Sixty percent of those who suffer from acute LBP recover in six weeks and up to 80-90% recover within 12 weeks. However, the recovery of the remaining patients with LBP is less certain. LBP accounts for 19% of all workers’ compensation claims in the United States.3 Americans spent at least $135 billion in 2016 on treating low back and neck pain, which was the highest expenditure among 154 conditions studied by the Department of the Institute for Health Metrics and Evaluation at the University of Washington.4
Scilex’s triple-strength SP-103 is an investigational, non-aqueous lidocaine topical system undergoing clinical development in acute LBP conditions. SP-103 builds on the learnings from Scilex’s FDA-approved product, ZTlido® (topical lidocaine system) 1.8%, because both products share the same adhesive drug delivery formulation and manufacturing technology. Scilex believes that, if approved, SP-103 could become the first FDA-approved lidocaine topical product for acute LBP indications. All current uses of topical lidocaine products for acute LBP are off-label. SP-103 has three times the drug load of ZTlido® (108 mg versus 36 mg) in the same adhesive system to potentially deliver a three-fold level of the drug within a targeted area, but retaining the convenience of a single topical system. Additionally, SP-103 is designed to deliver a localized dose of lidocaine that is three times greater than any lidocaine topical product that Scilex is aware of either on the market or in development. Scilex believes that, if approved, SP-103 may be able to address the limitations of prescription lidocaine patches in treating acute LBP by delivering a higher dose of lidocaine to the application site. As part of the lifecycle management, Scilex will also target localized musculoskeletal pain, acute and chronic pain conditions, and post-operation pain management, to focus on developing and commercializing non-opioid therapies for patients with acute and chronic pain. Scilex expects to complete its current Phase 2 trial of SP-103, randomized, double-blind, placebo controlled, parallel group, multicenter study to evaluate the safety and efficacy in subjects with acute lower back pain (LBP) in 10 U.S. sites, in Q1-2023. The outcome should enable planning of subsequent Phase 3 trial(s). ClinicalTrials.gov link: Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain - Full Text View - ClinicalTrials.gov
Under Section 561A(f)(2) of the United States Federal Food, Drug, and Cosmetic Act, Scilex is required to make our expanded access policy for SP-103 (lidocaine topical system) 5.4% publicly available by September 10, 2022 (within 15 days of the signature date of the FDA Fast Track letter).
Scilex Holding Company and Vickers Vantage Corp. I (Nasdaq: VCKA) (“Vickers”), a special purpose acquisition company sponsored by Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd, have entered into a definitive business combination agreement ("BCA") on March 17, 2022. Upon the closing of the transaction, the combined company (the “Combined Company”) will be renamed Scilex Holding Company, and its common stock and warrants to purchase common stock are expected to be listed on Nasdaq under the ticker symbol “SCLX” and “SCLXW”, respectively. The boards of directors of each of Vickers, Scilex and Sorrento have unanimously approved the proposed transaction. The closing of the transaction, which is expected to occur in the third quarter or early fourth quarter of 2022, is subject to the approval of Vickers’s and Scilex’s shareholders and the satisfaction or waiver of certain other customary closing conditions.
Are you still invested Brandwhineylady in this stock?
The ship is sinking, and the good Dr. is drilling holes in the bottom to let the water out...
Since it's documented Whales are buying .
What we waiting for the ship to leave the shore.
Dia76, Seems like big tutes are accumulating. Got this from an ST poster.
——————————-
SRNE
VANGUARD Adds 17,683,000 SRNE Shares
Kudos to Bonanzaa36 for catching this.
According to Fintel tonight, multiple Vanguard funds
reported new ownership in SRNE today, including
Vanguard Total Stock Market Index Fund: 10,897,884/
sh., Vanguard Extended Market Index: 6,058,370/sh,
plus 2 other Vanguard funds combined buys
727,900/shhttps://fintel.io/so/us/srne
On Aug. 12 in a 13F SEC quarterly filing, Vanguard Group
Inc. reported owning 20,896,424/sh. at 6/29/22,
which equaled 4.64% ownership in SRNE. SEC requires
any ownership greater than 5% to be reported within 10
days which would explain the need for today's filing.
Assuming no change from 6/30, the combined ownership
puts Vanguard's SRNE position at approx. 38,580,000
or 8.57%. On 6/30/22, State Street owned 8.81% and
Blackrock 7.55%.
On 6/30, 36.25% of SRNE float was held by institutions it
now looks like institutional ownership in SRNE holds over
40% of the float. Whales are buying !!!
Last time I have been here. Not sure of the value and likely will not be back. Funny the agenda I see here is oddly from the complaining poster I see posting the same content on "some other board" How does that happen? Is it contrived? No Don't? Don't answer. Like I say, there's no value.
Nothing personal, ....."But just because yo head's shaped like a bullet, don't make you no hotshot, cowboy"
Exactly Ez! I would get out instead of pouting.
I'm saying why be miserable in a stock you don't trust .
It's like having a wife you got to watch 25 hour's a day.
So... your saying no one here knows anything about the company. Interesting.
Wait, what happened to all those “billion” dollar Covid products? When I say “billion” I mean what the idiot dumped into them.
Followers
|
281
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
14953
|
Created
|
03/09/07
|
Type
|
Free
|
Moderators |
While being laser-focused on just one objective can have its advantages, having a wider-based remit can be just as effective, if done well.
That is certainly the opinion of Alliance Global analyst James Molloy when evaluating Sorrento’s prospects.
So, what’s on offer from the Sorrento menu in the near-term?
The company has already filed an EUA for COVI-STIX, a 15-minute nasal swab antigen test for SARS-CoV-2, in the US and Mexico, and the test could be launched as early as 1H21.
Accurate COVID tests are still needed in the US and around the globe, and Molloy expects the assay to gain EUA approval and could “rapidly approach $500M in sales as soon as 2022.“
SRNE's 8-minute SARS-CoV-2 antibody test COVID-TRACK could swiftly follow in its footsteps with an EUA anticipated to be filed in the year’s first half, too. “This could easily be another $500million+ near term opportunity,” Molloy said.
Furthermore, the company’s two neutralizing antibody treatments, COVI-DROPS and COVI-AMG, against SARS-CoV-2, could be launched in 2022. Each of these, as well, have the potential to bring in more than $500 million in sales, according to the analyst
The company’s non-opioid pain pipeline also has several late-stage catalysts.
Fast tracked by the FDA, Phase 3 data for sciatica pain candidate SP-102 should be available this year, while RTX for OsteoArthritis (OA) knee pain and intractable cancer pain will kick-off Phase 2 and Phase 3 studies, respectively, in 2021. Both target “substantial market opportunities.”
Last but not least is Abivertinib, the company's oncology lead candidate, indicated for non-small-cell lung cancer (NSCLC) and B-cell lymphomas, and currently in Phase 3 trials in China with top line data anticipated in 1H21.
To this end, based on the progress of the company's pipeline, Molloy sees significant gains in SRNE's future. The analyst rates the stock a Buy and his $35 price target implies a hefty 277% upside. (To watch Molloy’s track record, click here)
Overall, Sorrento currently has few, yet very positive analysts tracking its progress. With Buy ratings only – 3, in total - the stock has a Strong Buy consensus rating. There’s plenty of upside projected, too; At $28.67, the average price target suggests gains of ~209% over the next 12 months. (See SRNE stock analysis on TipRanks)
4955 Directors Place
San Diego, CA 92121
Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Sorrento’s multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”, “DAR-T™”), antibody-drug conjugates (“ADCs”), and clinical stage oncolytic virus (“Seprehvir™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-GUARD™, COVI-AMG™, COVI-SHIELD™, Gene-MAb™, COVI-MSC™ and COVI-DROPS™; and diagnostic test solutions, including COVI-TRACK™, COVI-STIX™ and COVI-TRACE™.
Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido® was approved by the FDA on February 28, 2018.
For more information visit?www.sorrentotherapeutics.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |